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Helicobacter pylori colonizes approximately 50% of the world’s population, and it is
the cause of chronic gastritis, peptic ulcer disease, and gastric cancer. The increase
of antibiotic resistance is one of the biggest challenges of our century due to its
constant increase. In order to identify an alternative or adjuvant strategy to the standard
antibiotic therapy, the in vitro activity of newly synthesized Silver Ultra-NanoClusters
(SUNCs), characterized by an average size inferior to 5 nm, against clinical strains
of H. pylori, with different antibiotic susceptibilities, was evaluated in this study. MICs
and MBCs were determined by the broth microdilution method, whereas the effect of
drug combinations was determined by the checkerboard assay. The Minimum Biofilm
Eradication Concentration (MBEC) was measured using AlamarBlue (AB) assay and
colony-forming unit (CFU) counts. The cytotoxicity was evaluated by performing the
MTT assay on the AGS cell line. The inhibitory activity was expressed in terms of
bacteriostatic and bactericidal potential, with MIC50, MIC90, and MBC50 of 0.33 mg/L
against planktonic H. pylori strains. Using the fractional inhibitory concentration index
(FICI), SUNCs showed potential synergism with metronidazole and clarithromycin. The
biofilm eradication was obtained after treatment with 2×, 3×, and 4× MIC values.
Moreover, SUNCs showed low toxicity on human cells and were effective in eradicating
a mature biofilm produced by H. pylori. The data presented in this study demonstrate
that SUNCs could represent a novel strategy for the treatment of H. pylori infections
either alone or in combination with metronidazole.
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INTRODUCTION
Helicobacter pylori (H. pylori) colonizes approximately 50% of the world’s population, with a
wide variation in the prevalence of the microorganism among regions and countries (Hooi et al.,
2017). H. pylori is associated with the development of chronic gastritis and peptic ulcer disease
(Eshraghian, 2014), and in 1994, it was classified as type one carcinogen (International Agency
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for Research on Cancer (IARC) 2019). Epidemiological studies
indicate that H. pylori eradication is associated with a decrease of
incidence of gastric cancer (Kosunen et al., 2011) that represents
the third most common cancer worldwide with a survival rate
longer than 5 years after the diagnosis in 1 over 5 patients affected
by this malignancy (Grande et al., 2010; Hooi et al., 2017). The
failure of the antibiotic treatment may be due to several factors
such as improper regimen, poor patient compliance, internalizing
bacteria, gene mutations, transfer of resistance genes, and biofilm
formation (Hu et al., 2017). H. pylori has been defined as a
“quasi-species” for its wide genetic variability. In fact, it has
been demonstrated that H. pylori strains isolated from different
patients displayed a high degree of variability for the acquisition
of new DNA sequences (Taylor et al., 1992; Suerbaum, 2000;
Grande et al., 2010). Many studies showed the co-colonization in
the same patient of multiple H. pylori strains characterized by the
resistance or susceptibility to the same antibiotic. Recombination
events can occur in the same patient during H. pylori infection
due to the adaptation of a single strain to stressful stimuli
such as sub-inhibitory antibiotic concentrations as well as to
mixed infections deriving from the host colonization by different
H. pylori strains in time (Grande et al., 2010). In addition,
H. pylori can produce a well-structured biofilm characterized
by the presence of outer membrane vesicles (OMVs) associated
with extracellular DNA (eDNA) (Cole et al., 2004; Cellini et al.,
2005; Yonezawa et al., 2009; Grande et al., 2015). It has been
demonstrated that the eDNA associated with OMVs facilitates
cell-to-cell binding and contributes to the stability of the biofilm
matrix. Moreover, the nucleic acid is protected by the vesicle
structures guaranteeing both delivery and release of the genetic
information and important proteins in other bacterial cells, and
H. pylori pathogenesis and survival (Grande et al., 2015; Ronci
et al., 2019). In addition, Yonezawa et al. (2011) demonstrated
the key role of a 22-kDa protein delivered by OMVs in the
development of the biofilm of H. pylori TK1402. A biofilm
can be defined as a complex tridimensional structure in which
cellular aggregates are immersed in a self-produced matrix of
extracellular polymeric substances (EPS) (Flemming et al., 2016).
Biofilm formation is a multistep regulated process in which
cellular adherence, EPS secretion and detachment of bacteria
from the maturing biofilm, are controlled by the regulation of
several genes (Grande et al., 2014).
Helicobacter pylori cells aggregation and biofilm formation
guarantee antibiotic tolerance versus the drugs commonly used
in anti-Helicobacter therapy as well as the protection from the
host immune system. The variability in the composition and
structure of H. pylori biofilm suggests the use of multi-targeted
or combination therapies. In fact, the tolerance against the
antimicrobial drugs might be due to both the slow penetration
of drugs through the EPS matrix and the presence of viable
but not culturable (VBNC) cells characterized by a metabolic
dormancy (Sisto et al., 2000; Dakal et al., 2016). Therefore,
the evaluation of H. pylori strain susceptibility versus the
antimicrobial drugs in vitro, traditionally carried out only on
the planktonic phenotype, does not represent a reliable predictor
of the efficacy of the antimicrobials in the human stomach
(Yonezawa et al., 2015). In fact, Yonezawa et al. (2015) and
Yonezawa et al. (2013) demonstrated that H. pylori biofilm
development increased the resistance to clarithromycin at MIC
levels by up to 4-fold in 2-day biofilms and to 16-fold in 3-
day biofilms; thus, H. pylori biofilm phenotype induces the
generation of clarithromycin resistance mutations. In conclusion,
as previously reported by Yonezawa et al. (2015), the study
of new H. pylori eradication strategies using biofilm-dissolving
molecules or compounds may provide advantages in resolving
H. pylori infections.
For the last few years, the antibiotic resistance represents
one of the biggest problems of global health due to the
constant increase. More than 50 antibiotics are currently under
clinical development, but only a few of them are innovative
and can get to the market. The prophylaxis by vaccination
is also under preclinical or clinical investigation, but licensed
vaccines for H. pylori infection are not yet available. Therefore,
the therapy improvement remains the only way to fight this
infectious disease.
The triple therapy, consisting of a proton-pump inhibitor
(PPI) and two different antimicrobials, has been considered the
standard therapy for the H. pylori eradication for the last 20 years.
The increase of the failure rates of the triple therapy recorded in
many countries such as those in Europe, as well as Korea, Japan,
and China, has been due to an excessive use of antibiotics as
well as to the empirical prescription of drugs (Ko et al., 2019).
Therefore, both a bismuth-containing quadruple therapy has
been recently recommended or clinical studies involving novel
potassium-competitive acid blockers (P-CABs instead of PPIs)
have been carried out (Mori and Suzuki, 2019) as the first-line
treatment of multidrug-resistant H. pylori strains, particularly
in areas of high clarithromycin resistance (Macías-García et al.,
2019). In 2017, the WHO classified the H. pylori resistance
to clarithromycin as “a high priority for antibiotic research
and development” (Savoldi et al., 2018). The resistance rate to
clarithromycin is 30% in Italy and Japan, and 40% and 50% in
Turkey and China, respectively (Yonezawa et al., 2013; Ghotaslou
et al., 2015; Kocazeybek and Tokman, 2016; Kuo et al., 2017).
A new approach should evaluate the use of alternative therapies
that does not induce resistance and are effective on sensitive or
resistant strain as well.
Based on these considerations, it is necessary to identify an
alternative or adjuvant strategy to the standard antibiotic therapy,
in order to reduce the development of any antibiotic resistance.
Many recent studies report the antimicrobial efficacy of metallic
nanomaterials, suggesting their potential use in medical devices,
burn dressing, water treatment, and food preservation (Vimbela
et al., 2017). Among all types of nanoparticles developed
and characterized, silver nanoparticles (AgNPs) gained strong
attention due to their inherent characteristic of acting as an
antimicrobial agent even in solid state. AgNPs showed a strong
antimicrobial activity against several Gram-positive and Gram-
negative microorganisms as well as an antibiofilm effect (Sondi
and Salopek-Sondi, 2004; Jain et al., 2009; Puca et al., 2019).
More in detail, AgNPs showed to be effective against
H. pylori strains at very low concentrations (Amin et al., 2012,
2014; Gurunathan et al., 2015; Saravanakumar et al., 2019).
They have also been tested on a large number of continuous
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and immortalized human cell lines in order to define their
cytotoxic effect. However, it is worth noting that, due to
the source variability and the differences in chemical–physical
properties of the nanoparticles used in several studies, the results
obtained are not easily comparable. Another important feature
of many phytogenic or chemically synthesized types of AgNPs
is the presence of surfactants, antioxidants, and/or organic
stabilizers (Mathur et al., 2018; Shanmuganathan et al., 2019). To
overcome these issues, we have recently synthesized novel Silver
Ultra-NanoClusters (SUNCs) (patent pending EP-18181873.3)
using a reproducible electrochemical approach. In contrast to
conventional AgNPs, our silver solutions are stable in ultrapure
water (UPW) and do not contain any surfactant or organic
stabilizer. Moreover, due to their exceptional nanosize (average
less than 5 nm), we named them SUNCs. Several studies indicate
that small nanoparticles induce greater cytotoxicity than larger
ones (Duran et al., 2010; Riaz et al., 2017; Siddiqi et al., 2018).
The smaller size of nanoparticles is related to greater surface
area that promotes higher agglomeration around the cell wall
with consequent membrane damage (Lu et al., 2019). In general,
the higher cytotoxicity of smaller nanoparticles can be explained
by different chemical–physical properties occurring when the
particle is formed by a lower aggregation of atoms. As an example,
we can consider the observed increased ROS production of small
nanoparticles as compared to that generated by the greater ones
(Hossain et al., 2019). Other mechanisms associated with these
silver-containing nanosystems are the disruption of the bacterial
membrane, uncoupling of the respiratory electron transport,
morphological changes (cytoplasm membrane detachment),
DNA replication impairment, and protein expression alteration
(Durán et al., 2016; Tang and Zheng, 2018). The aim of the
present study was the evaluation of the antimicrobial and
antibiofilm activity of these newly synthesized SUNCs, alone
and in association, against H. pylori strains characterized by
a different antibiotic susceptibility pattern. In addition, their
cytotoxic effect on AGS cells was also investigated. This is the first
report dealing with silver nanosystems endowed with an average
dimension inferior to 5 nm in order to comprehend the further
preclinical applications in vivo.
MATERIALS AND METHODS
Bacterial Strains and Cell Culture
Eight clinical isolates of H. pylori, including two highly resistant
to metronidazole (MNZ) (MIC > 8 mg/L), two resistant to
clarithromycin (CLR) (MIC > 0.5 mg/L), two resistant to
both MNZ and CLR, and two CLR, MNZ, and amoxicillin
(AMX) susceptible, were tested. The isolated strains have
been previously used in other research studies (Brenciaglia
et al., 1996; Sisto et al., 2000; Zengin et al., 2018). The
study did not require ethical approval, because all the isolates
were obtained as part of routine diagnostic microbiology
investigations; however, patients with duodenal ulcer or gastritis
enrolled at the Microbiology Laboratory of “Luigi Sacco” – ASST
Fatebenefratelli Sacco, Milan hospital, gave informed consent for
further future studies.
A reference strain of H. pylori (ATCC 43504) was used
as a control. Antimicrobial drugs were purchased from
Sigma-Aldrich (St. Louis, MO, United States) and prepared
according to the Clinical and Laboratory Standard Institute
(Clinical and Laboratory Standard Institute [CLSI] 2007).
The strains were cultured on Columbia agar base (Difco,
BD, San Jose, CA, United States) supplemented with 10%
(v/v) horse serum (Seromed, Biochrom, Germany) and
0.25% (w/v) bacto yeast extract (Difco, BD, San Jose,
CA, United States). Plates were incubated for 72 h at
37◦C under microaerophilic conditions (85% N2, 10%
CO2, 5% O2).
Human gastric adenocarcinoma AGS ATCC CRL-1739TM
cell line (American Type Culture Collection, Manassas, VA,
United States) was cultured in a 5% CO2 atmosphere in F-12
medium (HyClone, Logan, UT, United States) supplemented with
10% (v/v) decomplemented fetal bovine serum (FBS) (EuroClone
SpA, Milan, Italy).
Synthesis and Characterization of
SUNCs
Silver Ultra-NanoClusters were electrochemically synthesized by
means of an improved synthetic protocol in UPW without
stabilizing agents or other chemical components as previously
reported (Scotti et al., 2017). The novelty is based on
an “ultra small” size without changing the complex set of
physical and chemical properties (Z-Potential, Plasmonic UV-
Vis absorbance, concentration, stability in acid pH). The method
is protected by European Patent pending (EP-18181873.3). The
product was a yellow solution with an absorbance maximum
at 410 nm, odorless with a pH of 7–8, and characterized
by good stability (6 months). No change in absorbance
and λmax was observed after 1 h of incubation of SUNCs
at pH 3.5 in 0.01 M acetate buffer. A drastic decrease
of the plasmonic spectrum absorbance, without change of
the λmax, was observed after nitric acid treatment (0.1 M,
pH < 1) for 10 min at 25◦C. The complete disappearance
of the SUNCs UV-Vis spectrum is obtained after 60 min
of nitric acid (0.1 M final concentration) reaction at 60◦C
(Supplementary Figure S1; Ertürk, 2019). After each synthesis,
large nanoclusters were removed by flushing the solution
through 0.1-µm syringe filter devices (Whatman CYCLPR) and
subsequent centrifugation at 13,023 × g for 15 min. SUNCs
were characterized by transmission electron microscopy (TEM)
in terms of concentration, shape, and size determination (75 kV
ZEISS 109 equipped with Gatan-Orius SC200W-Model 830.10W
TEM CCD Camera). Particle concentration was taken at 75 kV
after evaporation of a drop of diluted SUNCs solution (1:5) on
300 mesh formvar-coated nickel grids and confirmed by ion-
selective electrode (ISE) technique. Evidence of non-spherical
shape was reported by TEM at 250,000× magnification, and the
images were elaborated with ImageJ software (ImageJ bundled
with Java 1.8.0_172).
Particle numbers and distribution were calculated
using a statistical software Origin ver. 9.0; their good
stability in the time (>1 year) was also verified
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(Scotti et al., 2017). The morphology and the elemental
composition of the particles were analyzed by scanning
electron microscopy (SEM) using a Phenom xl (Thermo
Fisher Scientific, United States) equipped with BDS, SED,
and EDS detectors (15 kW of acceleration voltages under
high vacuum level).
Antimicrobial Activity of SUNCs
Minimal inhibitory concentrations (MICs) and minimum
bactericidal concentrations (MBCs) were determined by
modified broth microdilution method as previously described
(Sisto et al., 2009). Briefly, twofold serial dilutions of SUNCs
were prepared in MegaCellTM RPMI-1640 medium (Sigma-
Aldrich, ST Louis, MO, United States) with 3% (v/v) fetal calf
serum (FCS) (HyClone, Logan, UT, United States). H. pylori
suspension was inoculated in each well to obtain a final
concentration of approximately 5× 105 CFU×well. The 96-well
microtiter plates were incubated at 37◦C under microaerophilic
conditions and examined after 72 h of incubation. The MBC
was determined as the lowest concentration of SUNCs able
to kill 99.9% of the starting inoculum. Aliquots (100 µl)
of each suspension without visible growth were spotted
on Columbia agar plates and incubated at 37◦C for 3–
5 days under microaerophilic conditions. The bactericidal
activity of SUNCs was also evaluated by killing curves. The
reference strain (ATCC 43504) and a clinical isolate (strain 23)
susceptible to metronidazole, clarithromycin, and amoxicillin
were used in the liquid culture study in the presence of
different SUNCs at 0.5 (0.5×), 1 (1×), and 2 times (2×) the
MIC. After 0, 24, and 48 h of incubation, the number of
colony-forming units (CFU) was assessed by plating serial
dilution of the samples onto Columbia agar plates. The rate
and extent of killing were expressed as viable count (log10
CFU/ml) against time.
Combination Effect of Metronidazole and
Clarithromycin With SUNCs
The combination effect of metronidazole and clarithromycin
and SUNCs was determined by checkerboard assay and
evaluated using fractional inhibitory concentration index
(FICI). The inoculum size and the culture conditions were
the same as those used for MIC determination. The FICI
was calculated from the fractional inhibitory concentration
(FIC) values of test compounds and antimicrobials. The
FICI ≤ 0.5, >4.0, and >0.5–4 were defined as synergistic,
antagonist, and non-synergistic or additive, respectively
(Doerne, 2014).
Evaluation of the Minimum Biofilm
Eradication Concentration
The biofilms were developed as previously described (Grande
et al., 2011). The antibiofilm effect of each sample was
determined by the evaluation of Minimum Biofilm Eradication
Concentration (MBEC). The MBEC was defined as the lowest
concentration of SUNCs that completely eradicated bacterial
biofilm formed in 96-well flat-bottom polystyrene microtiter
plates. Briefly, H. pylori ATCC 43504, H. pylori 23, H. pylori
110R, and H. pylori F40/499 were grown in BB plus 2% FCS
and 0.3% (w/v) glucose (Sigma-Aldrich). The ON broth cultures
were diluted till OD600 = 0.1 and diluted 1:10 to reach 106
CFU/ml. Two hundred microliters of the diluted broth cultures
was inoculated into 96-well flat-bottom polystyrene microtiter
plates (Eppendorf, Hamburg, Germany) and incubated at 37◦C
for 48 h under static conditions as previously described (Ronci
et al., 2019). At the end of incubation, the biofilms were
rinsed in phosphate-buffered saline (PBS) and SUNCs were
added to the mature biofilms at concentrations corresponding
to 1× MIC, 2× MIC, 3× MIC, 4× MIC, and 6× MIC.
Controls consisting of (i) H. pylori biofilms without the
FIGURE 1 | Transmission electron microscopy of SUNCs. SUNCs were electrochemically synthesized in ultrapure water. Large non-spherical nanocluster before
filtration. Magnification: 250,000× (a); ultra-nanoclusters after filtration. A drop of 1:5 diluted stock solution of SUNCs was allowed to evaporate onto 300 mesh
formvar-coated nickel grids, and then TEM image was taken at 75 kV by a ZEISS 109 microscope. Scale bar: 50 nm. Magnification: 85,000× (b).
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addition of SUNCs, (ii) BB plus 0.3% (w/v) glucose and 2%
of FCS and SUNCs, and (iii) just medium plus 0.3% (w/v)
glucose and 2% of FCS were inserted in the experiments.
The plates were then incubated at 37◦C for 24 h under
static conditions. The inhibitory effect was measured using
AlamarBlue (AB) assay (Thermo Fisher Scientific, Waltham, MA,
FIGURE 2 | Scanning electron microscopy analysis of SUNCs. Magnification: 85,000× (scale bar: 10 µm–15 kV). Spots 1, 2, and 3 revealed different distribution of
elements in the sample-different phases according to the SEM elemental analysis.
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United States) and CFU count. Three independent experiments
were performed in triplicate.
AB Biofilm Eradication Assay
The biofilms treated with different concentrations of SUNCs
(0.32 mg/L, 0.64 mg/L, 0.96 mg/L, 1.28 mg/L, and 1.92 mg/L)
were subsequently rinsed with PBS, and AB was added following
the manufacturer’s instructions. The plates were incubated for 4 h
at 37◦C and the absorbance was read. The percentage reduction
of AB in the treated and non-treated samples was calculated
using the formula indicated by the manufacturer. The AB MBEC
was defined as the lowest concentration of the test sample
resulting in ≤50% reduction of AB and a purplish/blue well,
4 h after the addition of the AB as previously demonstrated for
other microorganisms (Zengin et al., 2018). Three independent
experiments were performed in quadruplicate.
Cell Viability Evaluation Through CFU
Count and Live/Dead Staining
Colony-forming unit enumeration was performed to evaluate
bacterial cell viability in the biofilm phenotype after the
addition of AB solution. One hundred microliters of sample
solutions taken from the MBEC wells were used for CFU
count. Serial dilutions of the stock were performed in PBS
(pH 7.2), plated on Chocolate Agar (CA) and incubated at
37◦C under microaerophilic conditions, for 3–5 days. The
antibiofilm activity of SUNCs was confirmed by using the
Live/Dead BacLight bacterial viability kit (Life Technologies,
Carlsbad, CA, United States) according to the manufacturer’s
instructions, followed by fluorescence microscopy analysis as
previously reported (Zengin et al., 2018).
MTT Assay
Cell toxicity was evaluated using the MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide)
assay (Mossman, 1983). Briefly, AGS cells seeded in a 96-well
microtiter plates at 105 cell/ml were treated with serial dilution
of test compounds for 24 h, using DMSO (Sigma-Aldrich) as
control. At the end of incubation, MTT solution (Sigma) diluted
in PBS (5 mg/ml) was added, and incubation continued for
an additional 3 h at 37◦C in the dark. The plates were then
read on a microplate reader (Synergy IV, BioTek Instruments,
United States) using a test wavelength of 550 nm and a reference
wavelength of 650 nm. The optical density at 650 nm (OD
650) was subtracted from the OD 550 to eliminate non-specific
background. The effect was expressed as percentage of the
optical density measured in cultures that did not receive SUNCs
(100% viability).
Statistical Analysis
The differences in the means of the results between untreated and
treated H. pylori were analyzed by Student’s t test. The probability
value of p ≤ 0.05 was considered significantly different.
RESULTS
Characterization of SUNCs
Transmission electron microscopy and ISE analyses indicated
that SUNCs were characterized by a non-spherical shape
(Figure 1) at concentration of 20.9 mg/L (yellow solution, pH 7–
8). Statistical evaluation of TEM images demonstrated that the
average size of the nanoclusters is 1.83 nm ± 1.57 (5.366 points,
with min and max values of 1.15 and 13.75 nm, respectively).
The prevalent abundance of the silver metal (Ag◦) in the
formulation was assessed by the typical (UV-Vis) plasmonic
resonance spectrum (λmax at 410 nm) and by SEM. Analysis of
SEM images (Figure 2) indicated the presence of regions with
different elemental composition. Three different regions (spots 1,
2, and 3) showed the presence of different elements: Ag, O, Si, C,
Cl, and K. Ag◦ was predominant in all the evaluated areas. It is
interesting to note that for spots 1 and 2, the second abundant
element was oxygen, suggesting the possibility for Ag of being
present at different oxidation states. The plasmonic spectrum
showed no substantially variation in 0.01 M acetate buffer (Axson
et al., 2015; D’souza et al., 2015), indicating that pH 3.5 did not
affect the stability and the aggregation state of SUNCs. Only after
nitric acid treatment (pH < 1) for 1 h at 60◦C was a complete
disappearance of the plasmonic spectrum, without a shift of the
λmax, obtained. It is very likely that these drastic conditions can
induce the complete oxidation of metal silver in Ag+ without
macroaggregate formation (Ertürk, 2019).
TABLE 1 | Anti-Helicobacter pylori activity of SUNCs determined by the microdilution assay.
H. pylori strains SUNCs MIC/MBC (mg/L) MBC/MIC Antimicrobial susceptibility (MIC mg/L) References
Ro1 0.16/0.32 2 MNZ 1; CLR 64; AMX 0.016 Zengin et al., 2018
ATCC 43504 0.32/0.32 1 MNZ 128; CLR 0.064; AMX 0.032
23 0.32/0.32 1 MNZ 1; CLR 0.064; AMX 0.032 Sisto et al., 2000
110R 0.32/0.32 1 MNZ 128; CLR 0.03; AMX 0.016 Brenciaglia et al., 1996
F1 0.16/0.16 1 MNZ 2; CLR 4; AMX 0.064 Zengin et al., 2018
190 0.16/0.32 2 MNZ 1; CLR 0.032; AMX 0.032 Sisto et al., 2000
F40/499 0.32/0.32 1 MNZ 32; CLR 8; AMX 0.016 Zengin et al., 2018
F40/442 0.32/0.32 1 MNZ 64; CLR 0.015; AMX 0.015 Zengin et al., 2018
F34/497 0.32/0.32 1 MNZ 128; CLR 4; AMX 0.064 Zengin et al., 2018
MNZ, metronidazole; CLR, clarithromycin; AMX, amoxicillin.
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Determination of MICs and MBCs
The antibacterial activity of SUNCs was determined against
nine H. pylori strains. As shown in Table 1, SUNCs showed
antibacterial activity at MIC value ranging from 0.16 to
0.33 mg/L. No amoxicillin-resistant strain was available for
this study. In addition, the bactericidal activity was performed
by the microdilution method. MBC values were 1- to 2-
fold MIC concentrations, demonstrating the bactericidal
effects of SUNCs against H. pylori strains with different
antibiotic susceptibility.
Killing Kinetics
To evaluate the rate of killing of H. pylori by SUNCs, a kinetic
study was performed against the reference strain ATCC 43504
(Figure 3A) and the clinical isolate 23 (Figure 3B). The control
kinetics showed an exponential growth phase for the first 24 h,
FIGURE 3 | Kinetics of the killing activity of SUNCs against H. pylori ATCC 43504 and the clinical isolate H. pylori 23 by SUNCs. Antibacterial activity was evaluated
in RPMI Megacell with 3% FCS in the presence or absence of the SUNCs concentrations for different time points. The MIC value of H. pylori ATCC 43504 (A) and
clinical H. pylori 23 (B) was 0.33 mg/L. The data are expressed as mean CFU ± SD recovered from three different experiments performed in duplicate. Symbols:
filled circle, control; open diamond, 0.5× MIC; asterisk, 1× MIC; open square, 2× MIC.
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and a stationary phase for the following 24 h. SUNCs caused
a ∼7-log10 decrease in cell count at their MIC concentration
(0.33 mg/L) and the total killing within 24 h for both strains. The
limit of detection was 10 CFU/ml.
Combination Effect of Antibiotics With
SUNCs
Metronidazole and clarithromycin are the antimicrobials often
used as first-line treatment against H. pylori infections.
A checkerboard titration assay against two strains of H. pylori
was performed to verify a possible synergistic effect between
SUNCs and both antimicrobial drugs. The reference strain
(ATCC 43504) resistant to metronidazole (MIC > 16 mg/L)
and strain 23 sensitive to clarithromycin, amoxicillin, and
metronidazole were selected for this assay. SUNCs showed a
value very close to synergism (FICI 0.51) with clarithromycin
on both strains (Table 2), and with metronidazole on the
reference strain (FICI 0.55); a synergistic effect was obtained
on clinical H. pylori 23 (FICI 0.42) in combination with
metronidazole. These results are encouraging for a possible
synergistic interaction.
Evaluation of MBEC
The capability of SUNCs to eradicate the biofilm developed
by H. pylori after 2 days of incubation was determined by
using AB assay, CFU counting, and Live/Dead staining followed
by fluorescence microscopy analysis. The anti-biofilm effect
of SUNCs was evaluated against 3 H. pylori clinical strains
characterized by a different antimicrobial susceptibility pattern
and versus the reference strain. SUNCs showed a MBEC value of
1.28 mg/L versus H. pylori ATCC 43504 and H. pylori 23, a MBEC
value of 0.96 mg/L against H. pylori 110R and 0.64 mg/L against
H. pylori F40/499. The MBEC was determined by using the AB
assay based on resazurin reduction by viable cells, in resorufin,
a highly fluorescent red/purple compound (Figures 4A,B).
The efficacy of SUNCs on H. pylori biofilm eradication was
confirmed by both the reduction of CFU counts (Figure 4C) and
fluorescence microscopy analysis (Figure 5 and Supplementary
Figure S2). SUNCs caused a ∼1-log10 decrease in cell count
at 1.28 mg/L for H. pylori ATCC 43504 and H. pylori 23 and
a ∼7-log10 and ∼4-log10 decrease in cell count at 0.64 mg/L
for H. pylori 110R and H. pylori F40/499, respectively. The
fluorescence microscopy has been used as a qualitative analysis.
The images showed a visible disaggregation of the biofilm in all
SUNCs-treated strains confirming the CFU reduction (Figure 5
and Supplementary Figure S2). In particular, the addition of
SUNCs at concentrations corresponding to the MBEC of the
tested strains displayed a detachment of the biofilm or the
TABLE 2 | Checkerboard titration assay of SUNCs in combination
with MNZ and CLR.
FIC index MNZ FICI CLR FICI
≤0.5 (synergy) Strain 23 0.42 Strain 23 0.51
0.5 < FIC ≤ 4 (not
synergistic/additive interaction)
ATCC 43504 0.55 ATCC 43504 0.51
presence of few cells, many of which were dead (red fluorescence),
attached to the surface of the plates. We speculate that dead
cells tend to detach from the surface returning to the planktonic
phase. The cells that remain adhered are typically live cells,
tenaciously attached and dead cells still trapped in the EPS matrix
(Figures 5B,D,F,H and Supplementary Figures S2B,D,F,H).
This hypothesis was confirmed by the quantitative analysis based
on the CFU counts and AB assay. On the contrary, the untreated
biofilm was characterized by large aggregates of living cells
as indicated by the green fluorescence (Figures 5A,C,E,G and
Supplementary Figures S2A,C,E,G).
Effects of SUNCs Cells Viability
The effect of increasing concentrations of SUNCs (from 0.04 to
5.28 mg/L) was evaluated by MTT assay (Figure 6). SUNCs at
concentrations of 0.04, 0.08, 0.16, and 0.33 mg/L resulted in 100%
viability in AGS cells. A dose-dependent curve was obtained at
0.66 and 1.32 mg/L with 99% and 96% viability, respectively. At
2.64 mg/L, a dramatic decrease of viability was obtained (1%
viability). For this reason, it was not possible to calculate the
IC50. In order to evaluate the effects of SUNCs on different cell
lines, MTT assay on HaCaT and HMEC was also performed.
A dose-dependent toxicity was observed for HMEC with IC50
of 2.84 mg/L. HaCaT cells showed excellent viability also after
the treatment at SUNCs concentration of 5.28 mg/L (details in
Supplementary Material and Supplementary Figure S3).
DISCUSSION
The antimicrobial effect of different Ag+ ion formulations against
H. pylori has already been demonstrated in vivo and in vitro,
but few studies on the efficacy of AgNPs are present in the
literature do date. Very recently, a study about the effect of
biocompatible AgNPs against H. pylori MH179988 has been
published (Saravanakumar et al., 2019). The authors reported
a MIC of 18.14 mg/L, which is 8 to 10 times higher than
that found in the present study, highlighting the excellent
bactericidal efficacy of SUNCs. Due to the fact that many
studies also aimed at analyzing the toxic effects of silver
ions on human cells and in in vivo systems (acute exposure,
bioavailability, and bioaccumulation) (Stensberg et al., 2011) and
that the results often correlated the AgNP size and shape to
toxicity and ADME properties, we proposed the synthesis and
characterization of SUNCs endowed with dimensions <5 nm.
The SEM analysis indicates the presence, at the clusters’ surface,
of different Ag oxidative states whose higher reactivity might
explain the present results, although further investigations
are needed to better assess the peculiar chemical–physical
properties of these SUNCs.
The new silver formulation showed to be very effective against
different H. pylori strains tested with also a synergistic/additive
effect when combined with MNZ and CLR. In comparison with
MNZ alone, SUNCs were found to be active at their MIC value
approximately three- or sixfold lower than that of MNZ-sensitive
strains (MIC MNZ = 1 mg/L). In the AGS cell model, the
MTT assay showed that SUNCs were toxic at 2.62 mg/L, ∼4
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FIGURE 4 | The determination of the Minimum Biofilm Eradication Concentration (MBEC) against the H. pylori biofilm was evaluated by using the AB assay and the
CFU counting. Representative image of colorimetric MBEC evaluation by using AB. The black circle indicates the MBEC at 0.96 mg/L against H. pylori 110R (A). The
plot displays the percent reduction of AB in H. pylori biofilms at different concentrations of SUNCs compared to the corresponding untreated biofilms (B). CFU count
of SUNCs-treated and untreated biofilms (C). Data are presented as the mean of three replicates of three independent experiments. Controls correspond to 0 mg/L.
and 3 log2 dilutions higher than their MIC and/or MBC values,
respectively. These results clearly corroborated the limited cell
toxicity of our SUNCs with respect to commercially available
AgNPs characterized by greater dimensions, as reported in the
literature (Duran et al., 2010).
It has been widely demonstrated that H. pylori develops
biofilm both in vitro and in vivo (Cellini et al., 2005, 2008; Carron
et al., 2006; Grande et al., 2015). As reported by Koo et al. (2017)
the biofilm, initially defined as the “arcane behavior of bacterial
populations,” is considered today as a “principal virulence
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FIGURE 5 | Representative H. pylori biofilms stained with Live/Dead kit and analyzed using fluorescence microscopy. The green fluorescence indicates the live cells,
whereas the red fluorescence indicates the dead cells or cells with a damaged cell wall. Panels (a,c,e,g) show the untreated H. pylori biofilms, while panels (b,d,f,h)
show H. pylori biofilms treated with SUNCs at MBEC concentrations of 1.28 mg/L for H. pylori strains ATCC 43504 and 23, 0.96 mg/L for 110 R, and 0.64 mg/L for
F40/499. Scale bar: 5 µm.
factor in many localized chronic infections.” Biofilm infections
commonly recur after long periods of clinical quiescence, and
the key role of the EPS biofilm matrix in ensuring antimicrobial
tolerance to biofilms is widely demonstrated (Koo et al., 2017).
Among the common features of microbial biofilms, there is
the adherence. In fact, microorganisms adhere to both abiotic
materials such as plastic, metals, ceramics, etc., and biotic
surfaces such as tooth enamel, bone, skin, intestinal, vaginal
mucosa, and connective tissues, but also gastric mucosa as
demonstrated by Carron et al. (2006) who showed H. pylori
biofilm on human gastric mucosa. The multifactorial nature
of biofilm development and drug tolerance dictates important
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FIGURE 6 | Cell viability after treatment with SUNCs by MTT assay. AGS cells
were incubated for 24 h with different doses of SUNCs in F12 medium. The
effect is expressed as percentage of the optical density (OD) ± SD measured
in non-treated cultures (100% viability).
choices in the use of conventional antimicrobial drugs and
dictates the need for multi-target or combinatorial therapies,
particularly for H. pylori infections often associated with
multidrug-resistant strains toward antibiotics commonly used in
therapy such as clarithromycin. Therefore, the identification of
alternative therapies also associated with the use of antibiotics
commonly administered in clinical practice is necessary. The
microbial community of the biofilm may develop tolerance to
the antibiotics using different mechanisms such as the bacterial
conversion from the culturable status into a VBNC status (Sisto
et al., 2000), or the development of molecular pathways that
promote the bacterial persistence and survival (Flemming et al.,
2016). The efficacy of SUNCs has been tested to evaluate its
possible application for the treatment of H. pylori infections
associated with the biofilm development. The capability of
SUNCs to eradicate a 2-day preformed biofilm is probably due to
nanoparticle penetration through the biofilm EPS matrix, where
they are less susceptible to modifications compared to common
drugs (Dakal et al., 2016). On the other hand, Gurunathan
et al. (2015) demonstrated that AgNPs, with an average size
of 20 nm, caused dose-dependent decrease in cell viability and
biofilm formation as well as DNA fragmentation in H. pylori
and Helicobacter felis. Moreover, the data obtained showed the
capability of SUNCs to kill planktonic cells and to eradicate the
biofilms developed by all strains analyzed, regardless of their
pattern of sensitivity to antimicrobial drugs. The fluorescence
microscopy images show the presence of few cells adhered to the
plate surface in the SUNCs-treated samples, suggesting that the
SUNCs disrupt the biofilm. We hypothesize that SUNCs induce
cell death, promoting the cell detachment from the surface. The
few remaining cells, in fact, are live cells tenaciously attached
to the surface, or dead cells trapped in the EPS matrix. The
use of SUNCs as antimicrobial could reduce the drug resistance;
therefore, they could be used in combination with antimicrobial
drugs, leading also to a decrease in human cell toxicity due to
the reduction of the dosage. SUNCs could also be considered a
carrier for drug delivery as previously reported (Sharvil et al.,
2009). Furthermore, SUNCs at 1.32 mg/L killed 100% of bacteria
with 100% viability of AGS cells. Better results were obtained
with HaCaT cells that did not show any toxic effect at all
concentrations tested (Supplementary Figure S3). Many studies
report the low toxicity of AgNPs on different cell lines (Ivask
et al., 2014; Kanipandian et al., 2014; Chhibber et al., 2017).
Although in vitro, these results are very encouraging and suggest
differences in the toxicity mechanisms of SUNCs in different
biological systems. In addition, we showed that SUNCs are about
10-fold less toxic in mammalian than in bacterial cells, suggesting
different toxic mechanisms toward different biological systems.
A recent review (Ullah Khan et al., 2018) summarized the
toxic effects of AgNPs against bacteria, humans, fungi, viruses,
and protozoa. In general, low amount of AgNPs has excessive
potential against microorganisms, while at higher concentrations
(>10 µM), they are toxic to mammals. Conversely, other studies
report that humans can tolerate the assumption up to 16 mg with
low adverse effects (Kim et al., 2012, 2013; Amin et al., 2014),
or propose nanosilver as a pharmaceutical agent that is non-
toxic for humans (Lansdown, 2006). These findings, together
with the results reported here, strongly support the idea that a
possible SUNCs therapy in vivo against H. pylori infection could
be characterized by limited unwanted side effects (Ottoni et al.,
2019; Rodrigues et al., 2019). Indeed, the absorption of AgNPs
and their toxicity on human intestinal cells have been monitored
by Böhmert et al. (2014). The results suggest that AgNPs may
overcome the gastrointestinal juices in their particulate form
without forming large quantities of aggregates. Consequently,
the authors presumed that the particles can reach the intestinal
epithelial cells after ingestion with only a slight reduction
in their cytotoxic potential. Furthermore, a recent review
(McClements and Xiao, 2017) summarized the factors affecting
the gastrointestinal fate and toxicity of organic and inorganic
food-grade nanoparticles. Animal studies (Kim et al., 2008;
Gaillet and Rouanet, 2015 Hendrickson et al., 2016) corroborated
that AgNPs can be absorbed by the gastrointestinal tract into the
systemic circulation, and then be distributed throughout various
organs. However, only a small fraction (<1%) of ingested AgNPs
typically accumulate in tissues, which suggests that the majority
of them were excreted in the feces or urine (Hendrickson et al.,
2016). At the levels used in that study (2000 and 250 mg/kg body
weight for single and multiple doses, respectively), no toxicity
of the AgNPs was found after oral gavage. Another rat feeding
study reported no major toxic effects of ingestion of AgNPs over
a 28-day period (30, 300, and 1000 mg/kg day), but that there
was some slight liver damage at the highest levels used (Kim
et al., 2008). These results could be a good starting point in
order to relate the concentrations that should be delivered in vivo
with the effective concentrations observed here in vitro and, in
the future, in vivo pharmacokinetic assays will be performed to
assess the clinical efficacy and toxicity in a more complex model.
To the best of our knowledge, this is the first study reporting
the antimicrobial and anti-biofilm effects against H. pylori of
SUNCs with dimensions smaller than 5 nm and synthesized
in UPW. SUNCs could represent a novel strategy for the
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treatment of H. pylori infections especially in cases of multidrug
resistance or biofilm-producing strains. Although the strains
used in this study have different antibiotic susceptibility profiles,
further investigations on a greater collection of isolates with
established diverse genetic backgrounds are also to be considered.
Although the synergistic activity of SUNCs in association with
well-established antimicrobial drugs was performed versus two
strains, the data obtained suggest the potential use of SUNCs
in combination therapy with traditional antibiotics in order to
improve the management of H. pylori infection. Further, in vivo
pharmacokinetic assays will be performed to assess the clinical
efficacy and toxicity in a more complex model.
DATA AVAILABILITY STATEMENT
All datasets generated for this study are included in the
article/Supplementary Material.
AUTHOR CONTRIBUTIONS
FS and RG designed, interpreted the data, and wrote the article.
FS and VP performed the experimental work and acquisition
of data. MR, SC, and LS synthesized the nanoparticles and
performed the characterization and SEM/TEM analyses. GM
analyzed the data and performed the statistical analysis. RM and
AA critically revised the work and the final manuscript. RG
funded the project. All authors contributed to the article and
approved the submitted version.
FUNDING
This work was supported by the Ministero Italiano dell’Università
e della Ricerca (MIUR) FAR 2018 Grant, held by RG.
ACKNOWLEDGMENTS
This study was presented in part at the XXXIInd International
Workshop of the European Helicobacter & Microbiota Study
Group, Innsbruck, Austria, 2019 (Poster P1.18). We are grateful
to Dr. Nicole Cellucci and Dr. Maurizia Di Girolamo for their
excellent technical assistance.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fmicb.
2020.01705/full#supplementary-material
REFERENCES
Amin, M., Anwar, F., Janjua, M. R., Iqbal, M. A., and Rashid, U. (2012).
Green synthesis of silver nanoparticles through reduction with Solanum
xanthocarpum L. berry extract: characterization, antimicrobial and urease
inhibitory activities against Helicobacter pylori. Int. J. Mol. Sci. 13, 9923–9941.
doi: 10.3390/ijms13089923
Amin, M., Hameed, S., Ali, A., Anwar, F., Shahid, S. A., Shakir, I., et al.
(2014). Green synthesis of silver nanoparticles: structural features and in vivo
and in vitro therapeutic effects against Helicobacter pylori induced gastritis.
Bioinorg. Chem. Appl. 2014:135824.
Axson, J. L., Stark, D. I., Bondy, A. L., Capracotta, S. S., Maynard, A. D., Philbert,
N. A., et al. (2015). Rapid kinetics of size and pH-dependent dissolution and
aggregation of silver nanoparticles in simulated gastric fluid. J. Phys. Chem. C
119, 20632–20641. doi: 10.1021/acs.jpcc.5b03634
Böhmert, L., Girod, M., Hansen, U., Maul, R., Knappe, P., Niemann, B., et al.
(2014). Analytically monitored digestion of silver nanoparticles and their
toxicity on human intestinal cells. Nanotoxicology 8, 631–642. doi: 10.3109/
17435390.2013.815284
Brenciaglia, M. I., Fornara, A. M., Scaltrito, M. M., and Dubini, F. (1996). “In vitro”
development of metronidazole, erythromycin, amoxicillin and gentamicin
resistance in Helicobacter pylori. Int. J. Antimicrob. Agents 6, 223–226. doi:
10.1016/0924-8579(95)00040-2
Carron, M. A., Tran, V. R., Sugawa, C., and Coticchia, J. M. (2006). Identification
of Helicobacter pylori biofilms in human gastric mucosa. J. Gastrointest. Surg.
10, 712–717. doi: 10.1016/j.gassur.2005.10.019
Cellini, L., Grande, R., Di Campli, E., Traini, T., Di Giulio, M., Lannutti, S. N., et al.
(2008). Dynamic colonization of Helicobacter pylori in human gastric mucosa.
Scand. J. Gastroenterol. 43, 178–185.
Cellini, L., Grande, R., Traini, T., Di Campli, E., Di Bartolomeo, S., Di Iorio, D.,
et al. (2005). Biofilm formation and modulation of luxS and rpoD expression by
Helicobacter pylori. Biofilms 2, 119–127.
Chhibber, S., Gondil, V. S., Sharma, S., Kumar, M., Wangoo, N., and Sharma,
R. K. (2017). A novel approach for combating Klebsiella pneumoniae biofilm
using histidine functionalized silver nanoparticles. Front. Microbiol. 8:1104.
doi: 10.3389/fmicb.2017.01104
Clinical and Laboratory Standard Institute [CLSI] (2007). Performance Standards
for Antimicrobial Susceptibility Testing. Seventeenth Informational Supplement
M100–S17, Vol. 27. Wayne, PA: Clinical and Laboratory Standard Institute.
Cole, S. P., Harwood, J., Lee, R., She, R., and Guiney, D. G. (2004). Characterization
of monospecies biofilm formation by Helicobacter pylori. J. Bacteriol. 186,
3124–3132. doi: 10.1128/jb.186.10.3124-3132.2004
Dakal, T. C., Kumar, A., Majumdar, R. S., and Yadav, V. (2016). Mechanistic
basis of antimicrobial actions of silver nanoparticles. Front. Microbiol. 7:1831.
doi: 10.3389/fmicb.2016.01831
Doerne, C. D. (2014). When does 2 plus 2 equal 5? A review of antimicrobial
synergy testing. J. Clin. Microbiol. 52, 4124–4128. doi: 10.1128/jcm.01121-14
D’souza, S. L., Pati, R., and Kailasa, S. K. (2015). Ascorbic acid-functionalized
Ag NPs as a probe for colorimetric sensing of glutathione. Appl. Nanosci. 5,
747–753. doi: 10.1007/s13204-014-0371-9
Durán, N., Durán, M., de Jesus, M. B., Seabra, A. B., Fávaro, W. J., and Nakazato, G.
(2016). Silver nanoparticles: a new view on mechanistic aspects on antimicrobial
activity. Nanomedicine 12, 789–799. doi: 10.1016/j.nano.2015.11.016
Duran, N., Marcato, P. D., De Conti, R., Alves, O. L., Costa, F. T. M., and Brocchi,
M. (2010). Potential use of silver nanoparticles on pathogenic bacteria, their
toxicity and possible mechanisms of action. J. Braz. Chem. Soc. 21, 949–959.
doi: 10.1590/s0103-50532010000600002
Ertürk, A. S. (2019). Controlled production of monodisperse plant-mediated AgNP
catalysts using microwave chemistry: a desirability-function-based multiple-
response optimization approach. Chem. Select 4, 9300–9308. doi: 10.1002/slct.
201902197
Eshraghian, A. (2014). Epidemiology of Helicobacter pylori infection among the
healthy population in Iran and countries of the Eastern Mediterranean Region:
a systematic review of prevalence and risk factors. World J. Gastroenterol. 20,
17618–17625.
Flemming, H. C., Wingender, J., Szewzyk, U., Steinberg, P., Rice, S. A., and
Kjelleberg, S. (2016). Biofilms: an emergent form of bacterial life. Nat. Rev.
Microbiol. 14, 563–575. doi: 10.1038/nrmicro.2016.94
Frontiers in Microbiology | www.frontiersin.org 12 July 2020 | Volume 11 | Article 1705
fmicb-11-01705 July 29, 2020 Time: 17:38 # 13
Grande et al. Anti-Helicobacter pylori Activity of Silver Nanoclusters
Gaillet, S., and Rouanet, J. M. (2015). Silver Nanoparticles: their potential toxic
effects after oral exposure and underlying mechanisms - a review. Food Chem.
Toxicol. 77, 58–63. doi: 10.1016/j.fct.2014.12.019
Ghotaslou, R., Leylabadlo, H. E., and Asl, Y. M. (2015). Prevalence of antibiotic
resistance in Helicobacter pylori: a recent literature review. World J. Methodol.
5, 164–174.
Grande, R., Di Giulio, M., Bessa, L. J., Di Campli, E., Baffoni, M., Guarnieri, S., et al.
(2011). Extracellular DNA in Helicobacter pylori biofilm: a backstairs rumour.
J. Appl. Microbiol. 110, 490–498. doi: 10.1111/j.1365-2672.2010.04911.x
Grande, R., Di Giulio, M., Di Campli, E., Di Bartolomeo, S., and Cellini, L. (2010).
A model of Helicobacter pylori persistence in a case of gastric cancer. New
Microbiol. 33, 343–349.
Grande, R., Di Marcantonio, M. C., Robuffo, I., Pompilio, A., Celia, C., Di
Marzio, L., et al. (2015). Helicobacter pylori ATCC 43629/NCTC 11639 outer
membrane vesicles (OMVs) from biofilm and planktonic phase associated with
extracellular DNA (eDNA). Front. Microbiol. 6:1369. doi: 10.3389/fmicb.2015.
01369
Grande, R., Nistico, L., Sambanthamoorthy, K., Longwell, M., Iannitelli, A.,
Cellini, L., et al. (2014). Temporal expression of agrB, cidA, and alsS in the
early development of Staphylococcus aureus UAMS-1 biofilm formation and
the structural role of extracellular DNA and carbohydrates. Pathog. Dis. 70,
414–422.
Gurunathan, S., Jeong, J. K., Han, J. W., Zhang, X. F., Park, J. H., and Kim, J. H.
(2015). Multidimensional effects of biologically synthesized silver nanoparticles
in Helicobacter pylori, Helicobacter felis, and human lung (L132) and lung
carcinoma A549 cells. Nanoscale Res. Lett. 10:35.
Hendrickson, O. D., Klochkov, S. G., Novikova, O. V., Bravova, I. M., Shevtsova,
E. F., Safenkova, I. V., et al. (2016). Toxicity of nanosilver in intragastric studies:
biodistribution and metabolic effects. Toxicol. Lett. 241, 184–192. doi: 10.1016/
j.toxlet.2015.11.018
Hooi, J. K. Y., Lai, W. Y., Ng, W. K., Suen, M. M. Y., Underwood, F. E., Tanyingoh,
D., et al. (2017). Global prevalence of Helicobacter pylori infection: systematic
review and meta-analysis. Gastroenterology 153, 420–429.
Hossain, M. M., Polash, S. A., Takikawa, M., Shubhra, R. D., Saha, T., Islam, Z.,
et al. (2019). Investigation of the antibacterial activity and in vivo cytotoxicity of
biogenic silver nanoparticles as potent therapeutics. Front. Bioeng. Biotechnol.
7:239. doi: 10.3389/fbioe.2019.00239
Hu, Y., Zhu, Y., and Lu, N. H. (2017). Novel and effective therapeutic regimens
for Helicobacter pylori in an era of increasing antibiotic resistance. Front. Cell
Infect. Microbiol. 7:168. doi: 10.3389/fcimb.2017.00168
International Agency for Research on Cancer (IARC) (1994). “Working group
on the evaluation of carcinogenic risks to humans,” in Proceedings of the
Schistosomes, Liver Flukes and Helicobacter Pylori. IARC Working Group on the
Evaluation of Carcinogenic Risks to Human, 7–14 June 1994, Lyon. Vol. 61, 1.
Ivask, A., Kurvet, I., Kasemets, K., Blinova, I., Aruoja, V., Suppi, S., et al. (2014).
A size-dependent toxicity of silver nanoparticles to bacteria, yeast, algae,
crustaceans and mammalian cells In Vitro. PLoS One 9:e102108. doi: 10.1371/
journal.pone.0102108
Jain, J., Arora, S., Rajwade, J. M., Omray, P., Khandelwal, S., and Paknikar, K. M.
(2009). Silver nanoparticles in therapeutics: development of an antimicrobial
gel formulation for topical use. Mol. Pharm. 6, 1388–1401. doi: 10.1021/
mp900056g
Kanipandian, N., Kannan, S., Ramesh, R., Subramanian, P., and Thirumurugan,
R. (2014). Characterization, antioxidant and cytotoxicity evaluation of green
synthesized silver nanoparticles using Cleistanthus collinus extract as surface
modifier. Mater. Res. Bull. 49, 494–502. doi: 10.1016/j.materresbull.2013.09.016
Kim, J. S., Song, K. S., Sung, J. H., Ryu, H. R., Choi, B. G., Cho, H. S., et al.
(2013). Genotoxicity, acute oral and dermal toxicity, eye and dermal irritation
and corrosion and skin sensitization evaluation of silver nanoparticles.
Nanotoxicology 7, 953–960. doi: 10.3109/17435390.2012.676099
Kim, T., Kim, M., Park, H., Shin, U. S., Gong, M., and Kim, H. (2012). Size-
dependent cellular toxicity of silver nanoparticles. J. Biomed. Mater. Res. A 100,
1033–1043.
Kim, Y. S., Kim, J. S., Cho, H. S., Rha, D. S., Kim, J. M., Park, J. D., et al.
(2008). Twenty-eight-day oral toxicity, genotoxicity, and gender-related tissue
distribution of silver nanoparticles in sprague-dawley rats. Inhal. Toxicol. 20,
575–583. doi: 10.1080/08958370701874663
Ko, S. W., Kim, Y. J., Chung, W. C., and Lee, S. J. (2019). Bismuth supplements
as the first-line regimen for Helicobacter pylori eradication therapy: systemic
review and meta-analysis. Helicobacter 24:e12565. doi: 10.1111/hel.12565
Kocazeybek, B., and Tokman, H. B. (2016). Prevalence of primary antimicrobial
resistance of H. pylori in Turkey: a systematic review. Helicobacter 21, 251–260.
doi: 10.1111/hel.12272
Koo, H., Allan, R. N., Howlin, R. P., Stoodley, P., and Hall-Stoodley, L. (2017).
Targeting microbial biofilms: current and prospective therapeutics strategies.
Nat. Rev. Microbiol. 15, 740–755. doi: 10.1038/nrmicro.2017.99
Kosunen, T. U., Pukkala, E., Sarna, S., Seppälä, K., Aromaa, A., Knekt, P., et al.
(2011). Gastric cancers in Finnish patients after cure of Helicobacter pylori
infection: a cohort study. Int. J. Cancer 128, 433–439. doi: 10.1002/ijc.25337
Kuo, Y. T., Liou, J. M., El-Omar, E. M., Wu, J. Y., Leow, A. H. R., Goh, K. L., et al.
(2017). Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific
region: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2,
707–715. doi: 10.1016/s2468-1253(17)30219-4
Lansdown, A. (2006). Biofunctional Textiles and Skin, Vol. 33. Basel: Karger
Publisher, 17–34. doi: 10.1159/isbn.978-3-318-01349-8
Lu, J., Zhang, S., Gao, S., Wang, P., Bond, P. L., and Guo, J. (2019). New insights
of the bacterial response to exposure of differently sized silver nanomaterials.
Water Res. 169:115205. doi: 10.1016/j.watres.2019.115205
Macías-García, F., Bastón-Rey, I., de la Iglesia-García, D., Calviño-Suárez, C.,
Nieto-García, L., and Domínguez-Muñoz, J. E. (2019). Bismuth-containing
quadruple therapy versus concomitant quadruple therapy as first-line treatment
for Helicobacter pylori infection in an area of high resistance to clarithromycin:
a prospective, cross-sectional, comparative, open trial. Helicobacter 24:12546.
Mathur, P., Jha, S., Ramteke, S., and Jain, N. K. (2018). Pharmaceutical aspects of
silver nanoparticles. Artif. Cells Nanomed. Biotechnol. 46(Suppl. 1.), 115–126.
doi: 10.1080/21691401.2017.1414825
McClements, D. J., and Xiao, H. (2017). Is nano safe in foods? Establishing the
factors impacting the gastrointestinal fate and toxicity of organic and inorganic
food-grade nanoparticles. NPJ Sci. Food 1:6. doi: 10.1038/s41538-017-0005-1
Mori, H., and Suzuki, H. (2019). Role of acid suppression in acid-related
diseases: proton pump inhibitor and potassium-competitive acid blocker.
J. Neurogastroenterol. Motil. 25, 6–14. doi: 10.5056/jnm18139
Mossman, T. (1983). Rapid colorimetric assay for cellular growth and survival:
application to proliferation and cytotoxicity assays. J. Immunol. Methods 65,
55–63. doi: 10.1016/0022-1759(83)90303-4
Ottoni, C. A., Maria, D. A., Gonçalves, P. J. R. O., de Araújo, W. L., and
de Souza, A. O. (2019). Biogenic Aspergillus tubingensis silver nanoparticles’
in vitro effects on human umbilical vein endothelial cells, normal human
fibroblasts, HEPG2, and Galleria mellonella. Toxicol. Res. 8, 789–801. doi: 10.
1039/c9tx00091g
Puca, V., Traini, T., Guarnieri, S., Carradori, S., Sisto, F., Macchione, N.,
et al. (2019). The antibiofilm effect of a medical device containing TIAB on
microorganisms associated with surgical site infection. Molecules 24:2280. doi:
10.3390/molecules24122280
Riaz, A. K. B., Nagy, A. M., Brown, R. P., Zhang, Q., Malghan, S. G., and Goering,
P. L. (2017). Silver nanoparticles: significance of physicochemical properties
and assay interference on the interpretation of in vitro cytotoxicity studies.
Toxicol. In Vitro 38, 179–192. doi: 10.1016/j.tiv.2016.10.012
Rodrigues, A. G., Romano de Oliveira Gonçalves, P. J., Ottoni, C. A., de Cássia
Ruiz, R., Morgano, M. A., de Araújo, W. L., et al. (2019). Functional textiles
impregnated with biogenic silver nanoparticles from Bionectria ochroleuca and
its antimicrobial activity. Biomed. Microdevices 21:56.
Ronci, M., Del Prete, S., Puca, V., Carradori, S., Carginale, V., Muraro, R., et al.
(2019). Identification and characterization of the α-CA in the outer mem brane
vesicles produced by Helicobacter pylori. J. Enzyme Inhib. Med. Chem. 34,
189–195. doi: 10.1080/14756366.2018.1539716
Saravanakumar, K., Chelliah, R., MubarakAli, D., Oh, D. H., Kathiresan, K.,
and Wang, M. H. (2019). Unveiling the potentials of biocompatible silver
nanoparticles on human lung carcinoma A549 cells and Helicobacter pylori. Sci.
Rep. 9:5787.
Savoldi, A., Carrara, E., Graham, D. Y., Conti, M., and Tacconelli, E. (2018).
Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review
and meta-analysis in World Health Organization regions. Gastroenterology 155,
1372–1382.
Frontiers in Microbiology | www.frontiersin.org 13 July 2020 | Volume 11 | Article 1705
fmicb-11-01705 July 29, 2020 Time: 17:38 # 14
Grande et al. Anti-Helicobacter pylori Activity of Silver Nanoclusters
Scotti, L., Angelini, G., Gasbarri, C., and Bucciarelli, T. (2017). Uncoated negatively
charged silver nanoparticles: speeding up the electrochemical synthesis. Mater.
Res. Express 4:105001. doi: 10.1088/2053-1591/aa8c39
Shanmuganathan, R., Karuppusamy, I., Saravanan, M., Muthukumar, H.,
Ponnuchamy, K., Ramkumar, V. S., et al. (2019). Synthesis of silver
nanoparticles and their biomedical applications – a comprehensive review.
Curr. Pharm. Des. 25, 2650–2660. doi: 10.2174/1381612825666190708185506
Sharvil, S. P., Dhumal, R. S., Varghese, M. V., Paradkar, A. R., and Khanna, P. K.
(2009). Synthesis and antibacterial studies of chloramphenicol loaded nano-
silver against Salmonella typhi. Synth. React. Inorg. Met. Org. Nano Met. Chem.
39, 65–72.
Siddiqi, K. S., Husen, A., and Rao, R. A. K. (2018). A review on biosynthesis
of silver nanoparticles and their biocidal properties. J. Nanobiotechnol. 16:14.
doi: 10.1186/s12951-018-0334-5
Sisto, F., Brenciaglia, M. I., Scaltrito, M. M., and Dubini, F. (2000). Helicobacter
pylori: ureA, cagA and VacA expression during conversion to the coccoid form.
Int. J Antimicrob. Agents 15, 277–282. doi: 10.1016/s0924-8579(00)00188-6
Sisto, F., Scaltrito, M. M., Russello, G., Bonomi, A., and Dubini, F. (2009).
Antimicrobial susceptibility testing of Helicobacter pylori determined by
microdilution method using a new medium. Curr. Microbiol. 58, 559–563.
doi: 10.1007/s00284-009-9368-0
Sondi, I., and Salopek-Sondi, B. (2004). Silver nanoparticles as antimicrobial agent:
a case study on E. coli as a model for Gram-negative bacteria. J. Colloid Interface
Sci. 275, 177–182. doi: 10.1016/j.jcis.2004.02.012
Stensberg, M. C., Wei, Q., McLamore, E. S., Porterfield, D. M., Wei, A.,
and Sepúlveda, M. S. (2011). Toxicological studies on silver nanoparticles:
challenges and opportunities in assessment, monitoring and imaging.
Nanomedicine 6, 879–898. doi: 10.2217/nnm.11.78
Suerbaum, S. (2000). Genetic variability within Helicobacter pylori. Int. J. Med.
Microbiol. 290, 175–181. doi: 10.1016/s1438-4221(00)80087-9
Tang, S., and Zheng, J. (2018). Antibacterial activity of silver nanoparticles:
structural effects. Adv. Healthc. Mater. 7:e1701503. doi: 10.1002/adhm.
201701503
Taylor, D. E., Eaton, M., Chang, N., and Salama, S. M. (1992). Construction of a
Helicobacter pylori genome map and demonstration of diversity at the genome
level. J. Bacteriol. 174, 6800–6806. doi: 10.1128/jb.174.21.6800-6806.1992
Ullah Khan, S., Saleh, T. A., Wahab, A., Khan, M. H. U., Khan, D., Ullah
Khan, W., et al. (2018). Nanosilver: new ageless and versatile biomedical
therapeutic scaffold. Int. J. Nanomed. 13, 733–762. doi: 10.2147/IJN.
S153167
Vimbela, G. V., Ngo, S. M., Fraze, C., Yang, L., and Stout, D. A. (2017). Antibacterial
properties and toxicity from metallic nanomaterials. Int. J. Nanomed. 12,
3941–3965. doi: 10.2147/ijn.s134526
Yonezawa, H., Osaki, T., Hanawa, T., Kurata, S., Ochiai, K., and Kamiya, S. (2013).
Impact of Helicobacter pylori biofilm formation on clarithromycin susceptibility
and generation of resistance mutations. PLoS One 8:e73301. doi: 10.1371/
journal.pone.0073301
Yonezawa, H., Osaki, T., and Kamiya, S. (2015). Biofilm formation by Helicobacter
pylori and its involvement for antibiotic resistance. Biomed. Res. Int.
2015:914791.
Yonezawa, H., Osaki, T., Kurata, S., Fukuda, M., Kawakami, H., Ochiai, K.,
et al. (2009). Outer membrane vesicles of Helicobacter pylori TK1402 are
involved in biofilm formation. BMC Microbiol. 9:197. doi: 10.1186/1471-2180-
9-197
Yonezawa, H., Osaki, T., Woo, T., Kurata, S., Zaman, C., Hojo, F., et al. (2011).
Analysis of outer membrane vesicle protein involved in biofilm formation of
Helicobacter pylori. Anaerobe 17, 388–390. doi: 10.1016/j.anaerobe.2011.03.020
Zengin, G., Menghini, L., Di Sotto, A., Mancinelli, R., Sisto, F., Carradori, S.,
et al. (2018). Chromatographic analyses, in vitro biological activities, and
cytotoxicity of Cannabis sativa L. essential oil: a multidisciplinary study.
Molecules 23:E3266.
Conflict of Interest: LS is the author of a pending European Patent (EP-
18181873.3).
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2020 Grande, Sisto, Puca, Carradori, Ronci, Aceto, Muraro, Mincione
and Scotti. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) and the copyright owner(s)
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Microbiology | www.frontiersin.org 14 July 2020 | Volume 11 | Article 1705
